Value of the Laparoscopic Approach in the Surgical Management of Resectable Hepatocellular Carcinoma
LapCHC
1 other identifier
interventional
252
1 country
17
Brief Summary
Hepatocellular carcinoma treated by laparotomy or laparoscopic Multicenter prospective, open, superiority, controlled, randomized, clinical trial The primary objective of the study will be to demonstrate the superiority of the laparoscopic approach over the open approach in reducing postoperative morbidity in HCC patients. Postoperative morbidity will be assessed using the Comprehensive Complication Index (CCI) within 90 days postoperatively or at any time during hospitalization
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable hepatocellular-carcinoma
Started May 2021
Longer than P75 for not_applicable hepatocellular-carcinoma
17 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
January 7, 2021
CompletedFirst Posted
Study publicly available on registry
March 10, 2021
CompletedStudy Start
First participant enrolled
May 21, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 30, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
May 7, 2027
ExpectedMay 28, 2025
May 1, 2025
3.9 years
January 7, 2021
May 22, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
The primary objective of the study will be to demonstrate the superiority of the laparoscopic approach over the open approach in reducing postoperative morbidity in HCC patients.
Postoperative morbidity will be assessed using the Comprehensive Complication Index (CCI) within 90 days postoperatively or at any time during hospitalization
90 days after inclusion
Secondary Outcomes (15)
Number of postoperative complications (grade at least 1 according to the Dindo-Clavien classification) within 90 days postoperatively or at any time during hospitalization.
90 days after inclusion
Number of postoperative complications (grade at least 3 according to the Dindo-Clavien classification) within 90 days postoperatively or at any time during hospitalization.
90 days after inclusion
All-cause mortality (grade 5 according to the Dindo-Clavien classification or a CCI of 100) within 90 days postoperatively or at any time during hospitalization.
90 days after inclusion
Occurrence of specific liver related complications (ascites, liver failure, biliary fistula, hemorrhage) within 90 days postoperatively or at any time during hospitalization.
90 days after inclusion
Occurrence of organ space and superficial surgical site infection (SSI) within 90 days postoperatively or at any time during hospitalization.
90 days after inclusion
- +10 more secondary outcomes
Study Arms (2)
Laparoscopic approach for liver resection of HCC
EXPERIMENTALlaparotomy
EXPERIMENTALInterventions
* Installations of the patient: the position of the patient will depend on both extent of resection and location of the lesion. * Absence of laparotomy with the exception of the extraction of the resected specimen and absence of costal retractors. * Use of laparoscopic specific devices: * Use of multiple (3-7) ports depending on the operator's preference and technical difficulty (mainly 5-6 ports for major liver resection). * Use of a laparoscopic camera system with 0° or 30° * Use of a dedicated laparoscopic ultrasound probe. * Use of specific laparoscopic devices for coagulation, parenchymal transection and sealing. * Placement of the resected specimen in a plastic bag and extraction without fragmentation, depending on the surgeon's preferenceand the diameter of the resected specimen
* Installation of the patient: patients will be placed in supine position, the surgeon operating on the right side of the patient and the assistant standing on the left side. * Incision: the type of incision will depend on both the nature of the resection and the operator's preference. Various incisions such as bi subcostal incision, J-shaped incision, right subcostal incision and midline incision can be used. * Use of open surgical instruments and devices for coagulation and parenchymal transection. These may include the crush-clamp technique or ultrasonic dissection for parenchymal transection, bipolar coagulation, clips, sutures or open vascular stapler for hemostasis and biliostasis. * Methylene blue injection through the cystic drain to rule out biliary leakage will be performed depending on the surgeon's preference.
Eligibility Criteria
You may qualify if:
- Male or female patient aged ≥ 18 years
- Presenting with solitary or multifocal resectable HCC
- Qualifying for both pure laparoscopic and open approaches
You may not qualify if:
- Physical or psychological status contraindicating the participation to the study
- Contraindication to surgery
- Contraindication to pneumoperitoneum
- ASA (American Society of Anesthesiologists) score IV-V
- Life expectancy \< 2 months
- Suspicion of mixed type tumor (Hepatocholangiocarcinoma) and fibrolamellar HCC
- Child-Pugh score \> B7
- Extra-hepatic involvement
- Liver resection requiring an associated vascular or biliary reconstruction
- Pregnancy and breast-feeding
- Tutorship, trusteeship
- Concurrent participation in other experimental trials concerning the same objective within 90 days following intervention
- No Affiliation to the French social security
- No Ability to give their consent and not written informed consent
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (17)
Chirurgie Digestive - CHU Amiens
Amiens, France, 80054, France
Chirurgie viscérale et digestive - CHU Besançon
Besançon, France, 25000, France
Chirurgie Hépatologie - Hôpital Beaujon
Clichy, France, 92110, France
Chirurgie Digestive et Hépatobiliaire - Hôpital Henri-Mondor
Créteil, France, 94010, France
Chirurgie Digestive et de l'Urgence - CHU Grenoble
Grenoble, France, 38700, France
Chirurgie Digestive et Transplantations - Hôpital Huriez
Lille, France, 59021, France
Chirurgie Générale, Digestive et de la Transplantation hépatique - Hôpital de la Croix Rousse
Lyon, France, 69317, France
Chirurgie Digestive - CHU Montpellier
Montpellier, France, 34090, France
Chirurgie digestive - Institut Mutualiste Montsouris
Paris, France, 75014, France
Cochin hospital
Paris, France, 75014, France
Chirurgie hépato-biliaire et greffe de foie - La Pitié
Paris, France, 75651, France
Chirurgie viscérale et digestive - CHU Rouen
Rouen, France, 76000, France
Chirurgie hépato-bilio-pancréatique et Transplantation - Hôpital Rangueil
Toulouse, France, 31059, France
Chirurgie digestive Oncologique Endocrinienne et Transplantation hépatique - CHU Tours
Tours, France, 37000, France
Centre hépatobiliaire de transplantation hépatique - Hopital Paul Brousse
Villejuif, France, 94800, France
Chirurgie Digestive - Hôpital La Timone
Marseille, 13005, France
CHU Rennes - Pontchaillou
Rennes, France
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
January 7, 2021
First Posted
March 10, 2021
Study Start
May 21, 2021
Primary Completion
April 30, 2025
Study Completion (Estimated)
May 7, 2027
Last Updated
May 28, 2025
Record last verified: 2025-05
Data Sharing
- IPD Sharing
- Will not share